Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer

Carmela Mennuni, Stefano Ugel, Federica Mori, Barbara Cipriani, Manuela Iezzi, Tania Pannellini, Domenico Lazzaro, Gennaro Ciliberto, Nicola La Monica, Paola Zanovello, Vincenzo Bronte, Elisa Scarselli

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

The telomerase reverse transcriptase, TERT, is an attractive target for human cancer vaccination because its expression is reactivated in a conspicuous fraction of human tumors. Genetic vaccination with murine telomerase (mTERT) could break immune tolerance in different mouse strains and resulted in the induction of both CD4+ and CD8+ telomerase-specific T cells. The mTERT-derived immunodominant epitopes recognized by CD8+ T cells were further defined in these mouse strains and used to track immune responses. Antitumor efficacy of telomerase-based vaccination was investigated in two cancer models closely resembling human diseases: the TRAMP transgenic mice for prostate cancer and a carcinogen-induced model for colon cancer. TERT overexpression in tumor lesions was shown in both models by immunohistochemistry, thus reinforcing the similarity of these tumors to their human counterparts. Repeated immunizations with mTERT-encoding DNA resulted in a significant delay of tumor formation and progression in both the prostate cancer and the colon cancer models. Moreover, evaluation of the intratumoral infiltrate revealed the presence of telomerase-specific T cells in vaccinated mice. The safety of vaccination was confirmed by the absence of histomorphologic changes on postnecropsy analysis of several organs and lack of adverse effects on blood cell counts. These results indicate that TERT vaccination can elicit antigen-specific immunosurveillance and imply this antigen as a potential candidate for preventive cancer vaccines.

Original languageEnglish
Pages (from-to)9865-9874
Number of pages10
JournalCancer Research
Volume68
Issue number23
DOIs
Publication statusPublished - Dec 1 2008

Fingerprint

Telomerase
Carcinogens
Vaccination
Growth
Colonic Neoplasms
Neoplasms
T-Lymphocytes
Prostatic Neoplasms
Antigens
Immunologic Monitoring
Immunodominant Epitopes
Immune Tolerance
Cancer Vaccines
Blood Cell Count
Transgenic Mice
Immunization
Immunohistochemistry
Safety
DNA

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer. / Mennuni, Carmela; Ugel, Stefano; Mori, Federica; Cipriani, Barbara; Iezzi, Manuela; Pannellini, Tania; Lazzaro, Domenico; Ciliberto, Gennaro; La Monica, Nicola; Zanovello, Paola; Bronte, Vincenzo; Scarselli, Elisa.

In: Cancer Research, Vol. 68, No. 23, 01.12.2008, p. 9865-9874.

Research output: Contribution to journalArticle

Mennuni, C, Ugel, S, Mori, F, Cipriani, B, Iezzi, M, Pannellini, T, Lazzaro, D, Ciliberto, G, La Monica, N, Zanovello, P, Bronte, V & Scarselli, E 2008, 'Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer', Cancer Research, vol. 68, no. 23, pp. 9865-9874. https://doi.org/10.1158/0008-5472.CAN-08-1603
Mennuni, Carmela ; Ugel, Stefano ; Mori, Federica ; Cipriani, Barbara ; Iezzi, Manuela ; Pannellini, Tania ; Lazzaro, Domenico ; Ciliberto, Gennaro ; La Monica, Nicola ; Zanovello, Paola ; Bronte, Vincenzo ; Scarselli, Elisa. / Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer. In: Cancer Research. 2008 ; Vol. 68, No. 23. pp. 9865-9874.
@article{96a2dc5a9de543ca96e24d94bba0c700,
title = "Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer",
abstract = "The telomerase reverse transcriptase, TERT, is an attractive target for human cancer vaccination because its expression is reactivated in a conspicuous fraction of human tumors. Genetic vaccination with murine telomerase (mTERT) could break immune tolerance in different mouse strains and resulted in the induction of both CD4+ and CD8+ telomerase-specific T cells. The mTERT-derived immunodominant epitopes recognized by CD8+ T cells were further defined in these mouse strains and used to track immune responses. Antitumor efficacy of telomerase-based vaccination was investigated in two cancer models closely resembling human diseases: the TRAMP transgenic mice for prostate cancer and a carcinogen-induced model for colon cancer. TERT overexpression in tumor lesions was shown in both models by immunohistochemistry, thus reinforcing the similarity of these tumors to their human counterparts. Repeated immunizations with mTERT-encoding DNA resulted in a significant delay of tumor formation and progression in both the prostate cancer and the colon cancer models. Moreover, evaluation of the intratumoral infiltrate revealed the presence of telomerase-specific T cells in vaccinated mice. The safety of vaccination was confirmed by the absence of histomorphologic changes on postnecropsy analysis of several organs and lack of adverse effects on blood cell counts. These results indicate that TERT vaccination can elicit antigen-specific immunosurveillance and imply this antigen as a potential candidate for preventive cancer vaccines.",
author = "Carmela Mennuni and Stefano Ugel and Federica Mori and Barbara Cipriani and Manuela Iezzi and Tania Pannellini and Domenico Lazzaro and Gennaro Ciliberto and {La Monica}, Nicola and Paola Zanovello and Vincenzo Bronte and Elisa Scarselli",
year = "2008",
month = "12",
day = "1",
doi = "10.1158/0008-5472.CAN-08-1603",
language = "English",
volume = "68",
pages = "9865--9874",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "23",

}

TY - JOUR

T1 - Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer

AU - Mennuni, Carmela

AU - Ugel, Stefano

AU - Mori, Federica

AU - Cipriani, Barbara

AU - Iezzi, Manuela

AU - Pannellini, Tania

AU - Lazzaro, Domenico

AU - Ciliberto, Gennaro

AU - La Monica, Nicola

AU - Zanovello, Paola

AU - Bronte, Vincenzo

AU - Scarselli, Elisa

PY - 2008/12/1

Y1 - 2008/12/1

N2 - The telomerase reverse transcriptase, TERT, is an attractive target for human cancer vaccination because its expression is reactivated in a conspicuous fraction of human tumors. Genetic vaccination with murine telomerase (mTERT) could break immune tolerance in different mouse strains and resulted in the induction of both CD4+ and CD8+ telomerase-specific T cells. The mTERT-derived immunodominant epitopes recognized by CD8+ T cells were further defined in these mouse strains and used to track immune responses. Antitumor efficacy of telomerase-based vaccination was investigated in two cancer models closely resembling human diseases: the TRAMP transgenic mice for prostate cancer and a carcinogen-induced model for colon cancer. TERT overexpression in tumor lesions was shown in both models by immunohistochemistry, thus reinforcing the similarity of these tumors to their human counterparts. Repeated immunizations with mTERT-encoding DNA resulted in a significant delay of tumor formation and progression in both the prostate cancer and the colon cancer models. Moreover, evaluation of the intratumoral infiltrate revealed the presence of telomerase-specific T cells in vaccinated mice. The safety of vaccination was confirmed by the absence of histomorphologic changes on postnecropsy analysis of several organs and lack of adverse effects on blood cell counts. These results indicate that TERT vaccination can elicit antigen-specific immunosurveillance and imply this antigen as a potential candidate for preventive cancer vaccines.

AB - The telomerase reverse transcriptase, TERT, is an attractive target for human cancer vaccination because its expression is reactivated in a conspicuous fraction of human tumors. Genetic vaccination with murine telomerase (mTERT) could break immune tolerance in different mouse strains and resulted in the induction of both CD4+ and CD8+ telomerase-specific T cells. The mTERT-derived immunodominant epitopes recognized by CD8+ T cells were further defined in these mouse strains and used to track immune responses. Antitumor efficacy of telomerase-based vaccination was investigated in two cancer models closely resembling human diseases: the TRAMP transgenic mice for prostate cancer and a carcinogen-induced model for colon cancer. TERT overexpression in tumor lesions was shown in both models by immunohistochemistry, thus reinforcing the similarity of these tumors to their human counterparts. Repeated immunizations with mTERT-encoding DNA resulted in a significant delay of tumor formation and progression in both the prostate cancer and the colon cancer models. Moreover, evaluation of the intratumoral infiltrate revealed the presence of telomerase-specific T cells in vaccinated mice. The safety of vaccination was confirmed by the absence of histomorphologic changes on postnecropsy analysis of several organs and lack of adverse effects on blood cell counts. These results indicate that TERT vaccination can elicit antigen-specific immunosurveillance and imply this antigen as a potential candidate for preventive cancer vaccines.

UR - http://www.scopus.com/inward/record.url?scp=57149090284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57149090284&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-08-1603

DO - 10.1158/0008-5472.CAN-08-1603

M3 - Article

VL - 68

SP - 9865

EP - 9874

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 23

ER -